JP2013522302A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522302A5
JP2013522302A5 JP2013500127A JP2013500127A JP2013522302A5 JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5 JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5
Authority
JP
Japan
Prior art keywords
yeast
immunotherapy composition
interferon
based immunotherapy
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013500127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028359 external-priority patent/WO2011115914A1/en
Publication of JP2013522302A publication Critical patent/JP2013522302A/ja
Publication of JP2013522302A5 publication Critical patent/JP2013522302A5/ja
Withdrawn legal-status Critical Current

Links

JP2013500127A 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 Withdrawn JP2013522302A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31377410P 2010-03-14 2010-03-14
US31377610P 2010-03-14 2010-03-14
US31377510P 2010-03-14 2010-03-14
US61/313,774 2010-03-14
US61/313,776 2010-03-14
US61/313,775 2010-03-14
US37089910P 2010-08-05 2010-08-05
US61/370,899 2010-08-05
US40785910P 2010-10-28 2010-10-28
US61/407,859 2010-10-28
PCT/US2011/028359 WO2011115914A1 (en) 2010-03-14 2011-03-14 Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy

Publications (2)

Publication Number Publication Date
JP2013522302A JP2013522302A (ja) 2013-06-13
JP2013522302A5 true JP2013522302A5 (enExample) 2014-05-01

Family

ID=44649537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500127A Withdrawn JP2013522302A (ja) 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療

Country Status (4)

Country Link
US (1) US20130121964A1 (enExample)
EP (1) EP2547792A4 (enExample)
JP (1) JP2013522302A (enExample)
WO (1) WO2011115914A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676783C (en) 2007-02-02 2016-04-05 Globeimmune, Inc. Improved methods for producing yeast-based vaccines
BRPI0809247A2 (pt) 2007-03-19 2014-09-09 Globeimmune Inc Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
KR102046449B1 (ko) 2011-03-17 2019-11-19 글로브이뮨 효모-브라큐리 면역요법 조성물
EA030381B1 (ru) 2011-06-14 2018-07-31 Глоубиммьюн, Инк. Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
US9653272B2 (en) 2012-06-26 2017-05-16 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
CN104797259A (zh) * 2012-07-03 2015-07-22 奇默里克斯公司 治疗逆转录病毒感染的方法和相关剂量方案
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CN113419058B (zh) * 2014-04-11 2025-04-01 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
WO2016096800A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Biomarkers for hbv treatment response
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
WO2016159178A1 (ja) * 2015-03-30 2016-10-06 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CN107787372A (zh) * 2015-07-15 2018-03-09 豪夫迈·罗氏有限公司 Hbv 治疗应答的生物标志物
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
RU2623151C2 (ru) * 2015-11-03 2017-06-22 Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России Способ прогнозирования динамики фиброза печени у пациентов с хроническим гепатитом С, генотипом 1, не ответивших на лечение пегилированными интерферонами и рибавирином
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3793576A4 (en) 2018-05-15 2022-04-06 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP2008516610A (ja) * 2004-10-18 2008-05-22 グローブイミューン，インコーポレイテッド 酵母を用いた慢性ｃ型肝炎感染の治療
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP5469744B2 (ja) * 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition

Similar Documents

Publication Publication Date Title
JP2013522302A5 (enExample)
Sherman et al. Entecavir therapy for lamivudine‐refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
Marcellin Hepatitis B and hepatitis C in 2009
HK1255463A1 (zh) Hbv衣壳组装抑制剂和干扰素的组合疗法
JP2012513479A5 (enExample)
Brunetto et al. Interferon therapy of chronic hepatitis B
JP2016531144A5 (enExample)
Mallet et al. The impact of human immunodeficiency virus on viral hepatitis
JP2015517528A5 (enExample)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
RU2015114543A (ru) Способы лечения гепатита с
JP2015528449A5 (enExample)
JP2013529627A5 (enExample)
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
JP2019505553A5 (enExample)
RU2015114566A (ru) Способы лечения гепатита с
CN102083435A (zh) 特拉匹韦给药方案
Marcellin et al. CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS: 476
Takkenberg et al. New developments in antiviral therapy for chronic hepatitis B
Chen et al. The current status of combination therapy of chronic hepatitis B.
Papatheodoridis Treatment of HBeAg‐negative chronic hepatitis B patients with nucleos (t) ide analogues
Sokal et al. Chapter 6.1. Pediatric chronic hepatitis B and C: 30 years of ESPGHAN clinical research and recommendations
Mahtab et al. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability: 424
Papatheodoridis et al. CHANGES OF SERUM HBSAG LEVELS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS UNDER LONGTERM THERAPY WITH NUCLEOS (T) IDE ANALOGUE (S): 1458